Melanotan I vs Melanotan II

How they're alike

Melanotan I and Melanotan II are both synthetic analogs of alpha-melanocyte-stimulating hormone (α-MSH) that were designed in the 1980s out of the University of Arizona melanocortin chemistry program. Both retain the conserved His-Phe-Arg-Trp receptor-binding tetrapeptide that defines α-MSH pharmacology; in a local BLOSUM62 alignment of their primary sequences, the only run of identity is the H-F-R-W "message" motif (4 of 6 aa identical across that segment), with everything outside it diverging. Both incorporate a D-phenylalanine substitution at the position equivalent to α-MSH Phe⁷, which stabilizes the active-receptor-binding conformation and confers protease resistance — a generally applicable design strategy in the melanocortin ligand series catalogued by Ericson (2017). Functionally, both agonize MC1R on epidermal melanocytes, activating the Gαs–cAMP–PKA–CREB–MITF cascade that drives tyrosinase induction and eumelanin synthesis (García-Borrón 2014); this is why both peptides produce UV-independent skin pigmentation when administered systemically. Both are taught and cited together in melanocortin-pathway reviews as part of the same chemical lineage (Cai 2016).

How they differ

The principal pharmacological difference is receptor selectivity. Melanotan I (afamelanotide; [Nle⁴,D-Phe⁷]-α-MSH) is a linear 13-residue peptide that keeps the full α-MSH backbone and is described in the melanocortin design literature as relatively MC1R-selective, with much weaker activity at MC3R, MC4R, and MC5R (Ericson 2017; Hruby 2011). Melanotan II is a truncated cyclic heptapeptide — the lactam bridge between Asp² and Lys⁷ locks a smaller scaffold around the H-F-R-W message, and the resulting compound is a non-selective agonist across MC1R, MC3R, MC4R, and MC5R. That broader agonism is precisely why Melanotan II additionally engages the hypothalamic MC4R pathway that governs appetite suppression and sexual arousal (Yeo 2021), and the MC5R pathway in sebaceous tissue — receptors that Melanotan I largely leaves alone (Cai 2016).

A second axis of difference is regulatory and developmental trajectory. Melanotan I was advanced by Clinuvel Pharmaceuticals as an orphan drug for erythropoietic protoporphyria and received EMA approval in 2014 and FDA approval in October 2019 under the brand Scenesse, in the form of a 16 mg poly(DL-lactide-co-glycolide) (PLGA) biodegradable subcutaneous implant administered by a certified healthcare provider every 60 days. Melanotan II's commercial development was abandoned by Palatin around 2000 in favour of the more MC4R-selective derivative bremelanotide (PT-141), and Melanotan II itself has never been approved anywhere — it exists only as a gray-market research chemical. A third structural difference flows from the first two: because Melanotan I retains the longer α-MSH backbone and a single conformation-stabilizing D-Phe substitution, it has a markedly different physicochemical profile (molecular weight ~1647 Da, free-peptide plasma half-life ~30 minutes, formulated as a sustained-release implant) compared with Melanotan II's compact cyclic heptapeptide (~1024 Da, no approved formulation).

Head-to-head clinical evidence

No head-to-head randomized clinical trial has directly compared Melanotan I and Melanotan II in the published literature available in this dossier — a PubMed search for papers naming both peptides in title or abstract returns zero comparative trials, and the two cards share only one reference in common, a melanocortin-ligand history review (Ericson 2017). The comparisons that exist are therefore indirect: receptor-selectivity profiling in vitro and at the level of pharmacological reviews. Hruby (2011) and Ericson (2017) catalogue the two compounds side by side in the broader melanocortin design literature, attributing Melanotan I's narrower side-effect spectrum to its MC1R selectivity and Melanotan II's bundled tanning-plus-appetite-plus-arousal effects to its non-selective profile. The closest analog to a controlled clinical comparison comes via the MC4R-selective derivative bremelanotide, whose Phase II program — including the placebo-controlled crossover work in premenopausal women with sexual arousal disorder by Diamond (2006) — separates out the MC4R-driven sexual-arousal arm of Melanotan II's pharmacology and confirms it can be obtained without MC1R-driven pigmentation. That dissection is a pharmacological argument for why Melanotan I (MC1R-selective) and Melanotan II (broad) produce different effect spectra, but it is not a head-to-head trial of the two peptides themselves.

Safety profile comparison

The two peptides have substantially different safety records, and the difference tracks both the receptor pharmacology and the supply chain. Melanotan I's safety profile is characterized in pivotal Phase III RCTs and 8+ years of post-marketing observational cohorts in EPP patients receiving the controlled-release PLGA implant under specialist supervision; the most common labeled adverse events are implant-site reactions (~21%), nausea (~19%), oropharyngeal pain (~7%), and fatigue (~6%), with expected generalized skin darkening as a pharmacological effect rather than a toxicity. Long-term post-marketing surveillance in the EPP cohort has not so far identified a clear melanoma signal, though MC1R activation on melanocytes is biologically a domain that continues to warrant monitoring (García-Borrón 2014).

Melanotan II's safety profile, by contrast, is constructed largely from case reports of self-administered gray-market product. Published reports document rhabdomyolysis, renal infarction, eruptive and atypical nevi, mole darkening, priapism, and at least one mucosal melanoma following nasal-spray use. Analytical studies of black-market Melanotan II have additionally documented contamination, mislabeling, and identity confusion with bremelanotide, so an unknown fraction of reported adverse events reflect product-quality issues rather than the molecule's intrinsic pharmacology. Critically, the EPP-cohort safety experience with Melanotan I does not extrapolate to cosmetic-tanning self-injection of either Melanotan I or Melanotan II from research-chemical sources — those are different doses, different routes, different populations, and different monitoring contexts.

Indication overview

Melanotan I (afamelanotide / Scenesse) is approved by the FDA (October 2019), EMA (December 2014), Australia's TGA, and Switzerland's Swissmedic, all for the prevention of phototoxicity in adults with erythropoietic protoporphyria. The approved supply chain is restricted: distribution is through Clinuvel-certified specialty centres only, the formulation is the 16 mg PLGA implant placed by a healthcare provider, and the indication is EPP exclusively. Melanotan I has additionally been investigated in Phase II trials for vitiligo (combined with narrowband UVB phototherapy) and a Phase IIa proof-of-concept study in acute ischaemic stroke; neither has progressed to regulatory approval. Melanotan II has no approved indication in any jurisdiction; the FDA, UK MHRA, Australia's TGA, and several Nordic regulators have issued consumer warnings against unapproved cosmetic-tanning peptide products. The most pharmacologically related approved drug derived from this chemical series is bremelanotide (Vyleesi), an MC4R-leaning derivative of Melanotan II that the FDA approved for hypoactive sexual desire disorder in premenopausal women on the basis of the MC4R-arousal mechanism characterized by Diamond (2006) — a reminder that the Melanotan II scaffold has produced an approved drug, but only after the broad melanocortin agonism was re-engineered toward a single receptor.